Citation only
via OpenAlex
Neovascular Age-Related Macular Degeneration
Daniele Veritti, Valentina Sarao, Paolo Lanzetta
Ophthalmologica · 2012 · ▲ 67 citations
Abstract
PURPOSE: Neovascular age-related macular degeneration (AMD) is a leading cause of blindness, with an increasing incidence as the elderly population expands. Large, multi-center, randomized, clinical trials have been conducted exploring the safety and efficacy of anti-VEGF treatments. This paper aims to discuss the safety and efficacy of pegaptanib, ranibizumab, aflibercept and bevacizumab. New therapeutic agents and treatment strategies are also discussed. PROCEDURES: Evidence available from prospective, multicenter, clinical studies and from a selective literature search is utilized to present the results of VEGF inhibition in neovascular AMD and to generate evidence-based recommendations. RESULTS: Anti-VEGF treatment is indicated in choroidal neovascularization with active disease and produces a significant benefit in visual acuity. CONCLUSIONS: With the advent of anti-VEGF therapy, the prognosis of choroidal neovascularization has changed dramatically. Data from well-conducted clinical trials suggest that approved anti-VEGF drugs are effective and well tolerated.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1159/000337154
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Veritti, D., Sarao, V., & Lanzetta, P. (2012). Neovascular Age-Related Macular Degeneration. <em>Ophthalmologica</em>. https://doi.org/10.1159/000337154
Vancouver
Veritti D, Sarao V, Lanzetta P. Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2012. doi:10.1159/000337154.
BibTeX
@article{daniele2012Neovas,
title = {Neovascular Age-Related Macular Degeneration},
author = {Daniele Veritti and Valentina Sarao and Paolo Lanzetta},
journal = {Ophthalmologica},
year = {2012},
doi = {10.1159/000337154},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ophthalmology 2012
Preprint · OA
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Royal Liverpool University Hospital 2009
Open access · US-GOV
Study of Macular Function During Anti-VEGF Treatment
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Vastra Gotaland Region 2020
Open access · US-GOV
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Mabwell (Shanghai) Bioscience Co., Ltd. 2021
Open access · US-GOV
A Multicenter, Randomized, Double-blind, Positive-controlled, Seamless Design Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (Code MW02) in the Treatment of Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Allergan 2007
Open access · US-GOV